Autolus Therapeutics Plc (NASDAQ: AUTL)
Autolus Therapeutics Plc Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Autolus Therapeutics Plc Company Info
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
News & Analysis
Why Autolus Therapeutics Stock Is Crashing Today
The biopharmaceutical company announced the pricing of a secondary stock offering.
Why Autolus Therapeutics Stock Jumped 25% Today
A private equity firm is taking a $100 million stake in the biotech.
Here's Why Autolus Therapeutics Is Surging Today
Potential licensing agreements with Moderna are giving investors reasons to cheer.
Why Autolus Therapeutics Stock Skyrocketed Today
The company announced encouraging clinical trial data for its experimental cell therapy, AUTO1.
Why Autolus Therapeutics Shares Are Plunging Today
Investors are reacting negatively to the biotech's public stock offering.
3 Companies To Watch For At November’s Society for Immunotherapy of Cancer Meeting
Due to the explosion in immuno-oncology in recent years, what was once a small scientific meeting near the end of the year has become a go-to event for drug developers.
Valuation
Earnings Transcripts
Autolus Therapeutics Plc (AUTL) Q1 2020 Earnings Call Transcript
AUTL earnings call for the period ending March 31, 2020.
Autolus Therapeutics Plc (AUTL) Q4 2019 Earnings Call Transcript
AUTL earnings call for the period ending December 31, 2019.
Autolus Therapeutics Plc (AUTL) Q3 2019 Earnings Call Transcript
AUTL earnings call for the period ending September 30, 2019.
Autolus Therapeutics Plc (AUTL) Q2 2019 Earnings Call Transcript
AUTL earnings call for the period ending June 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.